NEW YORK, Sept 26 – Gene Logic (Nasdaq: GLGC) said Tuesday it had reached a deal that would give Amersham Pharmacia Biotech K.K. the exclusive rights to market sell Gene Logic’s products in Japan.

Under the terms of the deal, Amersham Pharmacia Biotech K.K, the Japanese subsidiary of Amersham Pharmacia Biotech, will market and sell Gene Logic’s range of databases and software tools to Japanese pharmaceutical and biotech companies.

Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.